SOHO State of the Art Updates and Next Questions: Identifying and Treating “Progression” in Myelofibrosis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
SOHO State of the Art Updates and Next Questions: Identifying and Treating “Progression” in Myelofibrosis
Authors
Keywords
Disease progression, Ruxolitinib failure, Fedratinib, Imetelstat, Pelabresib, Luspatercept, Momelotinib, Pacritinib, KRT-232, JAK inhibitors
Journal
Clinical Lymphoma Myeloma & Leukemia
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-06-23
DOI
10.1016/j.clml.2021.06.008
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic
- (2021) Srdan Verstovsek et al. Future Oncology
- Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure
- (2020) Claire N. Harrison et al. AMERICAN JOURNAL OF HEMATOLOGY
- Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis
- (2020) Naveen Pemmaraju et al. BLOOD
- Fedratinib Induces Spleen Responses and Reduces Symptom Burden in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Low Platelet Counts, who were Either Ruxolitinib-Naïve or were Previously Treated with Ruxolitinib
- (2020) Claire N Harrison et al. BLOOD
- A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia
- (2020) Aaron T. Gerds et al. BLOOD
- The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic Implication
- (2020) Bridget K. Marcellino et al. Clinical Lymphoma Myeloma & Leukemia
- Management of myelofibrosis after ruxolitinib failure
- (2020) Claire N Harrison et al. ANNALS OF HEMATOLOGY
- ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial
- (2020) Stephen T. Oh et al. Blood Advances
- Transient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlin
- (2020) Bridget K. Marcellino et al. Blood Advances
- Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis
- (2020) Aaron T. Gerds et al. Blood Advances
- Luspatercept for the treatment of anemia in myelodysplastic syndromes (MDS) and primary myelofibrosis (PMF)
- (2019) Pierre Fenaux et al. BLOOD
- Aurora kinase A inhibition provides clinical benefit, normalizes megakaryocytes and reduces bone marrow fibrosis in patients with myelofibrosis
- (2019) Naseema Gangat et al. CLINICAL CANCER RESEARCH
- Lack of Gdf11 does not improve anemia or prevent the activity of RAP-536 in a mouse model of beta-thalassemia
- (2019) Amaliris Guerra et al. BLOOD
- Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study
- (2019) Raajit K. Rampal et al. BLOOD
- Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study.
- (2019) Anders Lindholm Sørensen et al. HAEMATOLOGICA
- How we treat myelofibrosis after failure of JAK inhibitors
- (2018) Animesh Pardanani et al. BLOOD
- Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis
- (2018) Ganesh Raghu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
- (2018) Claire N Harrison et al. Lancet Haematology
- Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis
- (2018) John Mascarenhas et al. JAMA Oncology
- Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy
- (2018) Jack W. Singer et al. Oncotarget
- Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms
- (2017) Gabriela S. Hobbs et al. HAEMATOLOGICA
- SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis
- (2017) Ruben A. Mesa et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
- (2017) Srdan Verstovsek et al. Journal of Hematology & Oncology
- Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses
- (2017) Srdan Verstovsek et al. Journal of Hematology & Oncology
- Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis
- (2017) A Pardanani et al. LEUKEMIA
- Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis
- (2017) Francesca Palandri et al. Oncotarget
- Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms
- (2017) Gabriela S. Hobbs et al. HAEMATOLOGICA
- Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
- (2017) Claire N Harrison et al. Lancet Haematology
- Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
- (2017) Ruben A Mesa et al. Lancet Haematology
- The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies
- (2016) V. Gupta et al. HAEMATOLOGICA
- A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
- (2016) Vikas Gupta et al. HAEMATOLOGICA
- Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis
- (2016) John O. Mascarenhas et al. HAEMATOLOGICA
- Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies
- (2016) Srdan Verstovsek et al. Journal of Hematology & Oncology
- A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis
- (2016) S Verstovsek et al. LEUKEMIA
- JAK2V617F allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy
- (2016) G Barosi et al. LEUKEMIA
- Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
- (2016) C N Harrison et al. LEUKEMIA
- Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis
- (2016) Haifa Kathrin Al-Ali et al. LEUKEMIA & LYMPHOMA
- The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies
- (2016) V. Gupta et al. HAEMATOLOGICA
- A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
- (2016) Vikas Gupta et al. HAEMATOLOGICA
- Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis
- (2016) John O. Mascarenhas et al. HAEMATOLOGICA
- Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib
- (2015) K. P. Patel et al. BLOOD
- Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis
- (2015) R. S. Komrokji et al. BLOOD
- The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis
- (2015) M. Deininger et al. BLOOD
- Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group
- (2015) N M Kröger et al. LEUKEMIA
- A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis
- (2015) Ayalew Tefferi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
- (2015) Animesh Pardanani et al. JAMA Oncology
- Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis
- (2014) Rajasekhar N V S Suragani et al. NATURE MEDICINE
- Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis
- (2013) Animesh Pardanani et al. AMERICAN JOURNAL OF HEMATOLOGY
- Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
- (2013) A. Tefferi et al. BLOOD
- Anti-transforming growth factor-β therapy in patients with myelofibrosis
- (2013) John Mascarenhas et al. LEUKEMIA & LYMPHOMA
- Dual PI3K/AKT/mTOR Inhibitor BEZ235 Synergistically Enhances the Activity of JAK2 Inhibitor against Cultured and Primary Human Myeloproliferative Neoplasm Cells
- (2013) W. Fiskus et al. MOLECULAR CANCER THERAPEUTICS
- Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors
- (2013) Michaela Waibel et al. Cell Reports
- Heterodimeric JAK–STAT activation as a mechanism of persistence to JAK2 inhibitor therapy
- (2012) Priya Koppikar et al. NATURE
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- p53 Lesions in Leukemic Transformation
- (2011) Ashot Harutyunyan et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK2V617F negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms
- (2011) M Nakatake et al. ONCOGENE
- PRM-151 (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis
- (2010) J.S. Duffield et al. DRUG NEWS & PERSPECTIVES
- Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele
- (2009) P. Guglielmelli et al. BLOOD
- TGF-β1–induced expression of human Mdm2 correlates with late-stage metastatic breast cancer
- (2009) Shinako Araki et al. JOURNAL OF CLINICAL INVESTIGATION
- The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis
- (2009) Ruben A. Mesa et al. LEUKEMIA RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now